Ashling Wahner

Associate Editor, OncLive

Ashling Wahner joined MJH Life Sciences in 2022. She produces OncLive's podcast, OncLive On Air, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors

October 25th 2024

Treatment with APR-1051 appears safe and well tolerated in patients with advanced solid tumors and select cancer-associated gene alterations.

Dr Saad on the Safety Profile of Darolutamide Plus ADT in mHSPC

October 25th 2024

Fred Saad, CQ, MD, FRCS, FCAHS, discusses the safety findings from the phase 3 ARANOTE trial investigating darolutamide plus ADT in patients with mHSPC.

Frontline Palbociclib Opens the Door to Subsequent CDK4/6 Inhibition in Metastatic Breast Cancer

October 25th 2024

Jairam Krishnamurthy, MD, FACP, discusses the selective use of CDK4/6 inhibitors after prior progression on these agents in patients with breast cancer.

Nivolumab Plus AVD Prolongs PFS vs Brentuximab Vedotin Plus AVD in Advanced-Stage Hodgkin Lymphoma

October 25th 2024

Nivolumab plus AVD prolonged median PFS vs brentuximab vedotin plus AVD in patients with stage III or IV advanced-stage classic Hodgkin lymphoma.

Dr Inra on the Role of the Surgeon in Early-Stage Lung Cancer

October 25th 2024

Matthew Lawrence Inra, MD, discusses the role of the thoracic surgeon in treatment decision-making for patients with early-stage lung cancer.

Dr Mok on the Efficacy of Taletrectinib in ROS1+ NSCLC

October 25th 2024

Tony S. K. Mok, BMSc, MD, FASCO, discusses efficacy findings from a pooled analysis of the TRUST-I and TRUST-II trials of taletrectinib in ROS1+ NSCLC.

Adjuvant Ribociclib Revamps HR+/HER2– Breast Cancer Management

October 24th 2024

Jairam Krishnamurthy, MD, FACP, discusses factors that influence his choice between ribociclib and abemaciclib in the adjuvant breast cancer setting.

Investigative Targeted Agents Are Set to Expand the BCG-Unresponsive NMIBC Treatment Paradigm

October 24th 2024

Yair Lotan, MD, discusses notable up-and-coming agents in the BCG-unresponsive non–muscle-invasive bladder cancer treatment armamentarium.

Patient Prioritization Is the Foundation for a Successful Neurologic Oncology Career: With D. Ross Camidge, MD, PhD; and Douglas Ney, MD

October 23rd 2024

Drs Camidge and Ney discuss Dr Ney’s journey to becoming a neurologic oncologist and his experience as a physician with Tourette syndrome.

NX-5948 Generates Responses in R/R Waldenström Macroglobulinemia

October 22nd 2024

Treatment with the BTK degrader NX-5948 led to responses in patients with relapsed/refractory Waldenström macroglobulinemia.

Individualized Bosutinib Dose Adjustments Lend a Manageable AE Profile in Pretreated CML

October 22nd 2024

Jorge Cortes, MD, discusses findings with bosutinib in CML and the importance of dose adjustment as a strategy for managing bosutinib-related AEs.

ONCT-534 Reduces PSA Levels, Is Tolerable in Relapsed/Refractory mCRPC

October 22nd 2024

ONCT-534 reduced prostate-specific antigen levels in patients with relapsed/refractory metastatic castration-resistant prostate cancer.

TG4001 Plus Avelumab Fails to Boost PFS in Recurrent/Metastatic, HPV16+ Cervical, Anogenital Tumors

October 22nd 2024

The addition of TG4001 to avelumab failed to improve progression-free survival in HPV16-positive cervical and anogenital tumors.

BCG-Unresponsive NMIBC Management Begins to Shift Away From Bladder Removal

October 22nd 2024

Yair Lotan, MD, discusses the treatment paradigm for BCG-unresponsive NMIBC, approved therapeutic options, and factors that influence treatment decisions.

Phase 1 Trials Provide Oncology Fellows With Valuable Clinical Research Experience: With Samuel A. Kareff, MD, MPH

October 21st 2024

Dr Kareff discusses the intersections between early-phase clinical research and meaningful mentorship experiences during oncology/hematology fellowship.

Telisotuzumab Adizutecan Represents a Novel c-Met–Targeting ADC in MET-Amplified CRC

October 21st 2024

John H. Strickler, MD, highlights the mechanism of action of telisotuzumab adizutecan and the rationale for targeting c-Met in colorectal cancer.

Long-Term IO-IO Data Contest the Role of Frontline TKIs in Advanced RCC

October 18th 2024

Alan Tan, MD, discusses the nuances of navigating combination regimens for patients with advanced renal cell carcinoma.

Dr Nowakowski on the Significance of the TakeAim Lymphoma Trial in PCNSL

October 17th 2024

Grzegorz S. Nowakowski, MD, discusses the potential implications of the TakeAim Lymphoma trial of emavusertib plus ibrutinib in patients with PCNSL.

FDA Approval Insights: Denileukin Diftitox in Relapsed/Refractory CTCL

October 17th 2024

Dr Foss discusses the significance of the FDA approval of denileukin diftitox for patients with relapsed/refractory CTCL.

Updated RAMP 201 Data to Support NDA Submission for Avutometinib/Defactinib Combo in Recurrent KRAS+ Ovarian Cancer

October 17th 2024

Updated RAMP 201 data will support an NDA submission to the FDA for avutometinib plus defactinib in recurrent low-grade serous ovarian cancer.

NEXT PAGE
PREVIOUS PAGE